egen-001 + folfox

**egen-001 + folfox** is an investigational combination therapy, composed of EGEN-001—a gene therapy agent—and FOLFOX, a chemotherapy regimen. - **EGEN-001** is a plasmid DNA therapy encoding interleukin-12 (IL-12), delivered via a synthetic polymer-based formulation. IL-12 stimulates immune responses against tumors by enhancing T-cell and natural killer cell activity. - **FOLFOX** consists of three pharmaceutical agents: folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. FOLFOX kills rapidly dividing cancer cells by interfering with DNA synthesis and function. - This combination has been explored primarily in advanced or recurrent epithelial ovarian cancer and other solid tumors, aiming to leverage both cytotoxic and immunostimulatory mechanisms for synergistic antitumor effects.

Other names

egen-001egen001egen 001folfoxoxaliplatin de gramontoxmdg